Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Tumor cells utilize inhibitory immune receptors to evade host immune responses.
• Key pathways involved in immune evasion include PD-1/PD-L1 and Tim-3/Gal-9.
• These pathways are implicated in the progression of various malignancies.

Purpose of the Study:

• To investigate the expression of Galectin-9 (Gal-9) and Programmed Death-Ligand 1 (PD-L1) in leukemic cells from patients with Chronic Lymphocytic Leukemia (CLL).
• To assess the correlation between Gal-9 and PD-L1 expression levels and clinical stages of CLL.
• To explore the potential of these molecules as therapeutic targets or prognostic biomarkers in CLL.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) were collected from 25 untreated CLL patients and 15 healthy controls.
• RNA was extracted, and relative mRNA expression of Gal-9 and PD-L1 was quantified using Real-Time PCR.
• Patients were staged according to the Rai staging system.

Main Results:

• Gal-9 and PD-L1 mRNA expression was significantly elevated in CLL patients compared to healthy controls (p<0.0001 and p=0.005).
• CLL patients in advanced clinical stages exhibited higher expression of both Gal-9 and PD-L1 compared to early stages (p<0.0001 and p=0.004).

Conclusions:

• Over-expression of Gal-9 and PD-L1 in CLL suggests their involvement in immune evasion mechanisms.
• These findings warrant further investigation into Gal-9 and PD-L1 as potential targets for CLL immunotherapy.
• Elevated Gal-9 and PD-L1 in advanced CLL stages indicate their utility as prognostic biomarkers for disease progression.